CalciMedica Q4 2024 Earnings Report

CalciMedica EPS Results

• Actual EPS: -$1.70
• Consensus EPS: -$2.40
• Beat/Miss: Beat by +$0.70
• One Year Ago EPS: N/A

CalciMedica Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

CalciMedica Announcement Details

• Quarter: Q4 2024
• Date: 3/27/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

CalciMedica (NASDAQ:CALC), Inc. (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia. Early-phase data suggest that CRAC channel inhibition can reduce inflammatory cytokine release and support organ function in critically ill patients.

CalciMedica pursues a development strategy that combines rigorous clinical evaluation with strategic collaborations to expedite potential regulatory approvals and commercialization. Operating primarily in the United States, the company works closely with academic centers and healthcare organizations to advance its pipeline. By targeting calcium signaling in innate immune cells, CalciMedica aims to fill unmet medical needs in acute inflammatory diseases and improve outcomes for high-risk patient populations.